Journal article icon

Journal article

Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO)

Abstract:
INTRODUCTION: FMS-like tyrosine kinase 3 (FLT3) mutations show variable detectability in relapse/refractory acute myeloid leukemia (AML) with unclear clonal evolution dynamics. METHODS: This prospective noninterventional study examined clonal evolution and outcomes from AML diagnosis to relapse/refractory disease occurrences. RESULTS: Of 650 patients included, 172 were FLT3-positive (FLT3pos) and 472 were FLT3-negative (FLT3neg; 99.1% testing rate; unknown FLT3 status, six patients). At first occurrence, the FLT3 testing rate decreased (57.0% [166/291]). Among tested patients, 45 had FLT3pos and 121 had FLT3neg AML. A gain or loss of mutations was seen in 15.6% (7/45) of patients with FLT3pos AML and 14.9% (18/121) of patients with FLT3neg AML. Median (95% confidence interval [CI]) overall survival was 22.8 (19.6, not estimable [NE]) months across patients (FLT3pos, NE;FLT3neg, 20.3 [15.2-23.7] months; hazard ratio [HR] [95% CI] 0.6 [0.5-0.8]). Median (95% CI) disease-free survival across patients was NE (26.3-NE) (FLT3pos, NE;FLT3neg, NE; HR [95% CI] 0.8 [0.6-1.1]). Median event-free survival (95% CI) was 11.8 (10.0-15.5) months in all patients (FLT3pos, 17.2 [11.0-NE] months;FLT3neg, 10.4 [8.4-13.2] months; HR [95% CI] 0.8 [0.6-1.0]). CONCLUSIONS: Dynamic changes in FLT3 mutation status were observed during these patients' disease course. FLT3pos status at baseline, but not at first occurrence, was associated with improved outcomes; other confounders should be considered. Timelier FLT3 mutation retesting may aid in personalizing treatment. Graphical abstract available for this article.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1007/s40487-026-00427-w

Authors

More by this author
Role:
Author
ORCID:
0000-0003-3387-5930
More by this author
Role:
Author
ORCID:
0000-0003-4892-9727


Publisher:
Springer
Journal:
Oncology and Therapy More from this journal
Publication date:
2026-03-11
Acceptance date:
2026-02-17
DOI:
EISSN:
2366-1089
ISSN:
2366-1070


Language:
English
Keywords:
Pubs id:
2389313
Local pid:
pubs:2389313
Source identifiers:
W7134901300
Deposit date:
2026-03-15
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP